Patients’ preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment.

This study has as objectives: To estimate the preferences of osteoporotic patients for medication attributes, and analyse data from seven European countries.

In total, 1124 patients completed the experiment, with a sample of between 98 and 257 patients per country. They found statistically significant differences in patients’ preferences for anti-osteoporosis medications between countries, especially for the mode of administration. Our findings emphasized that international treatment recommendations should allow for local adaptation, and that understanding individual preferences is important if we want to improve the quality of clinical care for patients with osteoporosis.

Rheumatology (Oxford). 2017 Apr 6. doi: 10.1093/rheumatology/kex071

Más información

Hiligsmann M, Dellaert BG, Dirksen CD, Watson V, Bours S, Goemaere S, Reginster JY, Roux C, McGowan B, Silke C, Whelan B, Diez-Perez A), Torres E, Papadakis G, Rizzoli R, Cooper C,Pearson G, Boonen A

Patrocinadores de la web
Laboratorios Rubió
Grupo Italfármaco
Gedeon Richter
Kyowa Kirin